Reliance Life Sciences is involved in
predictive diagnostics research in the
field of oncology, with the objective
of predicting increased risk of developing
a disease in the future based on a test
done on an asymptomatic person (person
who appears normal). Positive result only
provides information about a person's
risk of developing cancer. Negative result
indicates the individual's risk of cancer
is the same as that of general population.
Reliance Life Sciences is the only organization
doing BRCA 1/ BRCA 2 mutations testing
for familial breast cancer in India. Reliance
Life Sciences uses state-of-the-art technology
i.e. DNA sequencing -
'a gold standard' and the test shows 100
percent sensitivity and specificity. Reliance
Life Sciences offers both pre and post
genetic counselling and reports both the
alterations depicting the polymorphisms
observed and the mutations. Turn around
time (TAT) for BRCA1/2 is a record 15
days, which is the best TAT for BRCA1/2
globally. BRCA 1/2 TAT at most labs in
the world is approximately 3 to 6 months.
Reliance Life Sciences also offers predictive
tests for RET gene mutations for familial
medullary thyroid cancer and HPV (Human
Papilloma Virus) detection and typing
by nucleotide sequencing, for depicting
increased risk of cervical cancer.
To know more about predictive diagnostics
testing services available, click here
